Liquid stable virus vaccines
AssigneeIntervet Inc.
InventorsZhisong Qiao, Kevin O'Connell
Life of this patent
Estimating the term…
Abstract
The present invention discloses liquid stable vaccines that comprise a live attenuated virus, 10-30% sugar additive, and an amino acid. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
Claims21
A liquid stable vaccine that comprises a live attenuated canine or feline virus, 10-30% (w/v) sugar additive, and an amino acid;
- wherein the liquid stable vaccine has a pH of 6.0 to 8.0;
- wherein the amino acid is selected from the group consisting of arginine and methionine;
- wherein when the amino acid is arginine, its final concentration in the liquid stable vaccine is 0.15 to 0.6 M;
- and wherein when the amino acid is methionine, its final concentration in the liquid stable vaccine is 0.025 to 0.3 M;
- and
- wherein the live attenuated canine or feline virus is selected from the group consisting of a distemper virus, an adenovirus, a parvovirus, and a parainfluenza virus.
A method of making a liquid stable vaccine that comprises combining a therapeutically effective amount of a live attenuated canine or feline virus with a 10-30% (w/v) sugar additive, an amino acid, and a buffered solution at pH 6.0 to pH 8.0 to form a liquid stable vaccine;
- wherein the amino acid is selected from the group consisting of arginine and methionine;
- wherein when the amino acid is arginine, its final concentration in the liquid stable vaccine is 0.15 to 0.6 M;
- and wherein when the amino acid is methionine, its final concentration in the liquid stable vaccine is 0.025 to 0.3 M;
- and
- wherein the live attenuated canine or feline virus is selected from the group consisting of a distemper virus, an adenovirus, a parvovirus, and a parainfluenza virus.
Dependencies are inferred from the claim text.